Thera-SAbDab

CAROTUXIMAB

>   Structural Summary
TherapeuticCarotuximab
TargetENG
Heavy ChainEVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS
Light ChainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedNational Cancer Institute (USA), Santen Pharmaceutical, TRACON Pharmaceuticals, University of Alabama at Birmingham, University of Minnesota, Roswell Park Cancer Institute
Conditions Approvedna
Conditions ActiveWet age-related macular degeneration
Conditions DiscontinuedFallopian tube cancer, Ovarian cancer, Peritoneal cancer, Prostate cancer, Haemangiosarcoma, Choriocarcinoma, Glioblastoma, Liver cancer, Renal cell carcinoma, Soft tissue sarcoma, Breast cancer, Non-small cell lung cancer, Acute myeloid leukaemia, Colorectal cancer, Precursor B-cell lymphoblastic leukaemia-lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]